Here are the S-3 shelf registrations from Ligand Pharms General CVR (LGNYZ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow LGNYZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LGNYZ filings page.
Ligand Pharmaceuticals filed a Form S-3 shelf registration to offer up to $100,000,000 of common stock through an at-the-market sales agreement with Leerink Partners LLC. Sales may occur from time to time after the effective date and proceeds are payable to the issuer. The prospectus supplement states the company had 19,774,343 shares outstanding as of December 31, 2025. The sales agent may receive up to 3.0% of gross proceeds as compensation, and the number and timing of sales will vary with market conditions and company instructions.